Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dextromethorphan + bupropion
- Development stage
- Approved
- Lead developer
- Axsome Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dextromethorphan + bupropion is an oral, fixed-dose extended-release small-molecule combination marketed in the United States as **Auvelity** and developed by Axsome as AXS-05. Dextromethorphan is an uncompetitive N-methyl-D-aspartate receptor antagonist and sigma-1 receptor agonist, while bupropion inhibits cytochrome P450 2D6 to increase dextromethorphan exposure and also inhibits norepinephrine and dopamine reuptake. Auvelity is approved for major depressive disorder in adults and for agitation associated with dementia due to Alzheimer's disease. ([axsome.com](https://www.axsome.com/wp-content/uploads/2024/11/auvelity-prescribing-information.pdf))
- Brand names
- Auvelity
- Other names
- dextromethorphan and bupropiondextromethorphan hydrobromide + bupropion hydrochloridedextromethorphan-bupropiondextromethorphan/bupropion
02
Targets
NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)MOR (Mu opioid receptor)SIGMAR1 (Sigma non-opioid intracellular receptor 1)SERT (Sodium-dependent serotonin transporter)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on dextromethorphan + bupropion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dextromethorphan + bupropion.